Generic placeholder image

Recent Patents on Anti-Infective Drug Discovery


ISSN (Print): 1574-891X
ISSN (Online): 2212-4071

Novel Quercetin Glycosides as Potent Anti-MRSA and Anti-VRE Agents

Author(s): Abugafar M.L. Hossion and Kenji Sasaki

Volume 8 , Issue 3 , 2013

Page: [198 - 205] Pages: 8

DOI: 10.2174/1574891X08666131210124649

Price: $65


Each year in the United States, at least 2 million people become infected with bacteria that are resistant to antibiotics and at least 23,000 people die each year as a direct result of these infections (Threat report 2013). Vancomycin is an FDA approved antibiotic and is growing importance in the treatment of hospital infections, with particular emphasis on its value to fight against methicillin-resistant Staphylococcus aureus (MRSA). The increasing use of vancomycin to treat infections caused by the Gram-positive MRSA in the 1970s selected for drug-resistant enterococci, less potent than staphylococci but opportunistic in the space vacated by other bacteria and in patients with compromised immune systems. The dramatic rise of antibiotic-resistant bacteria over the past two decades has stressed the need for completely novel classes of antibacterial agents. This paper reports the recent patent review on the strategy for finding novel quercetinglycoside type antibacterial agents against vancomycin-resistant bacterial strains.

Keywords: Antibacterial, cell penetration, multidrug-resistant, quercetin, quercetin-O-glycosides, vancomycin.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy